Valuation: Becton, Dickinson and Company

Market Cap 48.93B 42.36B 39.59B 36.18B 68.19B 4,667B 69.25B 464B 182B 2,335B 184B 180B 7,775B P/E 2026 *
34.8x
P/E 2027 * 21.8x
Enterprise Value 64.57B 55.9B 52.25B 47.76B 89.99B 6,159B 91.4B 613B 240B 3,081B 242B 237B 10,262B EV / Sales 2026 *
3.35x
EV / Sales 2027 * 3.18x
Free-Float
73.18%
Yield 2026 *
2.18%
Yield 2027 * 2.22%
1 day+1.48%
1 week+5.54%
Current month+8.50%
1 month+16.00%
3 months+22.39%
6 months-9.89%
Current year-7.10%
1 week 146.35
Extreme 146.35
155.1
1 month 131.25
Extreme 131.25
155.1
Current year 121.45
Extreme 121.45
179.95
1 year 121.45
Extreme 121.45
179.95
3 years 121.45
Extreme 121.45
261
5 years 121.45
Extreme 121.45
264.8
10 years 121.45
Extreme 121.45
264.8
Manager TitleAgeSince
Chief Executive Officer 53 28/01/2020
Director of Finance/CFO 44 05/12/2025
Compliance Officer - 01/02/2023
Director TitleAgeSince
Director/Board Member 75 24/09/2002
Director/Board Member 71 26/07/2010
Chairman 53 28/04/2021
Change 5-day change 1-year change 3-year change Capi.($)
+1.48%+5.54% - - 48.17B
+0.75%+1.40%-19.11%+3.70% 187B
+2.58%+3.15%-3.74%+7.57% 112B
+1.42%+5.39%+13.98%+73.77% 61.15B
+2.38%+3.92%+35.52%+60.21% 54.39B
+1.57%+5.53%-7.17%-35.21% 48.17B
+3.42%+0.39%+11.15%-22.62% 31.98B
-4.03%-16.46% - - 30.91B
-0.55%+1.20%+46.12%-12.02% 24.92B
+0.61%+2.70%-1.62%+5.14% 23.15B
Average +0.96%+0.50%+9.39%+10.07% 63.64B
Weighted average by Cap. +1.25%+2.08%-0.13%+12.40%

Financials

2026 *2027 *
Net sales 19.28B 16.69B 15.6B 14.26B 26.86B 1,838B 27.28B 183B 71.77B 920B 72.38B 70.8B 3,063B 19.72B 17.07B 15.96B 14.59B 27.49B 1,881B 27.92B 187B 73.44B 941B 74.06B 72.45B 3,134B
Net income 1.35B 1.17B 1.09B 998M 1.88B 129B 1.91B 12.81B 5.03B 64.41B 5.07B 4.96B 215B 2.16B 1.87B 1.75B 1.6B 3.02B 206B 3.06B 20.53B 8.06B 103B 8.13B 7.95B 344B
Net Debt 15.65B 13.54B 12.66B 11.57B 21.8B 1,492B 22.14B 148B 58.25B 746B 58.75B 57.46B 2,486B 13.84B 11.98B 11.2B 10.24B 19.29B 1,320B 19.59B 131B 51.54B 661B 51.98B 50.85B 2,200B
Logo Becton, Dickinson and Company
Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical management systems (52.4%): medication delivery systems, pharmaceutical systems, advanced patient monitoring systems, etc.; - interventional medical equipment (23.9%): surgical instruments, urological care products, etc.; - diagnostic materials and clinical research and development tools (23.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, tools for studying genes and culturing cells, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (58.6%), Europe/Middle East/Africa (21.6%), Asia (14.2%) and other (5.6%).
Employees
72,000
Date Price Change
10/08/26 €154.40 +1.48%
07/08/26 €152.15 -1.27%
06/08/26 €154.10 +5.30%
05/08/26 €146.35 -0.81%
04/08/26 €147.55 +0.85%
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
179.63USD
Average target price
192.00USD
Spread / Average Target
+6.89%

Quarterly revenue - Rate of surprise